{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:14:28Z","timestamp":1788869668350,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.pnpbp.2011.12.013","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T12:47:49Z","timestamp":1325335669000},"page":"182-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study"],"prefix":"10.1016","volume":"37","author":[{"given":"Yuya","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Bies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.12.013_bb0005","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.pnpbp.2011.12.013_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.013_bb0185","series-title":"NONMEM user's guide, part I","author":"Beal","year":"1992"},{"issue":"6","key":"10.1016\/j.pnpbp.2011.12.013_bb0020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/npp.2011.10","article-title":"Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues","volume":"36","author":"Bedard","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.pnpbp.2011.12.013_bb0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.JGP.0000224330.73063.6c","article-title":"Population pharmacokinetics in geriatric psychiatry","volume":"14","author":"Bigos","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2011.12.013_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.pnpbp.2011.12.013_bb0035","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2011.12.013_bb0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.12.013_bb0190","series-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"issue":"1","key":"10.1016\/j.pnpbp.2011.12.013_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270009343694","article-title":"Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking","volume":"50","author":"Jin","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.pnpbp.2011.12.013_bb0055","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2011.12.013_bb0065","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2011.12.013_bb0060","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2011.12.013_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"2 Suppl.","key":"10.1016\/j.pnpbp.2011.12.013_bb0195","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2011.12.013_bb0080","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2011.12.013_bb0085","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/ajp.2007.164.4.630","article-title":"Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia","volume":"164","author":"Mizrahi","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2011.12.013_bb0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2011.12.013_bb0095","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pnpbp.2011.12.013_bb0100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/01.jcp.0000185341.55096.65","article-title":"\u201cExtended\u201d antipsychotic dosing: rationale and pilot data","volume":"25","author":"Remington","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.pnpbp.2011.12.013_bb0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4088\/JCP.09m05866yel","article-title":"\u201cExtended\u201d antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial","volume":"72","author":"Remington","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2011.12.013_bb0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data","volume":"5","author":"Sheiner","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.pnpbp.2011.12.013_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"10.1016\/j.pnpbp.2011.12.013_bb0120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.biopsych.2004.10.023","article-title":"Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats","volume":"57","author":"Turrone","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2011.12.013_bb0125","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/JGP.0b013e318172b42d","article-title":"Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan","volume":"16","author":"Uchida","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2011.12.013_bb0130","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4088\/JCP.v69n0811","article-title":"Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia","volume":"69","author":"Uchida","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2011.12.013_bb0135","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.2009.133","article-title":"Predicting age-specific dosing of antipsychotics","volume":"86","author":"Uchida","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pnpbp.2011.12.013_bb0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JGP.0b013e318198776d","article-title":"Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms","volume":"17","author":"Uchida","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2011.12.013_bb0145","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1176\/appi.ajp.2010.10030409","article-title":"Analysis of antipsychotic dose reduction","volume":"167","author":"Uchida","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.013_bb0200","unstructured":"Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, et al. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Therapeut Drug Monit (in press)."},{"issue":"4","key":"10.1016\/j.pnpbp.2011.12.013_bb0155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pnpbp.2011.12.013_bb0160","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.pnpbp.2011.12.013_bb0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2011.12.013_bb0170","first-page":"65","article-title":"Predicting dopamine D2 receptor occupancy following antipsychotic dose reduction: a pilot PET study","volume":"261","author":"Uchida","year":"2011","journal-title":"Eur Arch Clin Neurosci"},{"issue":"6","key":"10.1016\/j.pnpbp.2011.12.013_bb0175","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/appi.ajp.2009.09030358","article-title":"Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial","volume":"167","author":"Wang","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2011.12.013_bb0180","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0091270010387604","article-title":"Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study","volume":"51","author":"Wessels","year":"2011","journal-title":"J Clin Pharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611003782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611003782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:41:56Z","timestamp":1759520516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584611003782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0278584611003782"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.12.013","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}